Title:Dehydroandrographolide Inhibits Osteosarcoma Cell Growth and Metastasis by Targeting SATB2-mediated EMT VOLUME: 19 ISSUE: 14 Author(s):Xuefeng Liu, Yonggang Fan, Jing Xie, Li Zhang, Lihua Li* and Zhenyuan Wang*

Mar 28, 2018 differential diagnosis between osteosarcoma and dedifferentiated Galectin-1,6 NELL-17 and SATB 28 9 are reported as biomarkers for

SATB2 is a highly sensitive marker for osteosarcomatous differentiation in gynecologic tract carcinosarcoma, and is also highly specific when used to differentiate osteosarcoma from chondrosarcoma and rhabdomyosarcoma elements in these tumors. The sensitivity of SATB2 for osteosarcoma was 94%, and the specificity was 55%. Stronger-intensity staining was observed in osteosarcoma (P < 0.0001). Conclusions: SATB2 is a sensitive marker for osteosarcoma; however, it is not specific, with expression being observed in other high-grade primary bone sarcomas. SATB2 was a very sensitive marker for osteosarcoma: 100% on whole slides, and 94%, including tissue micro-array (TMA) data, as reported by David and Horvai.

Satb2 osteosarcoma

galectin-1 and NDRG1 as potential markers of osteosarcoma, but their practical utility in the diagnosis of bone tumor is unclear [7–10]. Given the role of SATB2 The utility of SATB2 expression in osteosarcomas and other bone and soft tissue Extra skeletal osteosarcoma is a high grade malignant mesenchymal Mar 28, 2018 differential diagnosis between osteosarcoma and dedifferentiated Galectin-1,6 NELL-17 and SATB 28 9 are reported as biomarkers for Oct 1, 2016 SATB2 has also been shown to be highly expressed in tumors of osteoblastic differentiation, including osteosarcomas and several benign bone Jun 4, 2019 Extensive and strong SATB2 expression indicates metastatic colon Metformin reduces SATB2-mediated osteosarcoma stem cell-like Mar 18, 2017 apply SATB2 and CK20 to assist in differentiating appendiceal Small cell osteosarcoma: clinicopathologic, immunohistochemical, and Jan 12, 2018 Intriguingly, SATB2 was documented to be a sensitive marker for bone tumors, especially osteosarcoma [18–20], which might serve as a Apr 10, 2019 Small cell osteosarcoma: SATB2. Considering a small cell ostosarcoma can be positive for MIC2, similar to Ewing sarcoma, further molecular Apr 13, 2016 SATB2. Special AT-rich sequence binding protein 2 2q33. • Small cell osteosarcoma.

SATB2 is a marker of osteoblastic differentiation in benign and malignant mesenchymal tumours. Although SATB2 is not specific for osteosarcoma, it has the potential to be a useful adjunct in some settings, particularly in the distinction between hyalinized collagen and osteoid. SATB2 is a highly sensitive marker for osteosarcomatous differentiation in gynecologic tract carcinosarcoma, and is also highly specific when used to differentiate osteosarcoma from chondrosarcoma and rhabdomyosarcoma elements in these tumors.

Testföremål inkluderade Osteocalcin, Osteonectin, Osteopontin, Vim, S-100, Actin, SMA, CK, NSE, CD99, SATB2, MDM2, CDK4, Ki67 och P53, men alla

Stronger-intensity staining was observed in osteosarcoma (P < 0.0001). Conclusions: SATB2 is a sensitive marker for osteosarcoma; however, it is not specific, with expression being observed in other high-grade primary bone sarcomas. SATB2 was a very sensitive marker for osteosarcoma: 100% on whole slides, and 94%, including tissue micro-array (TMA) data, as reported by David and Horvai. These results are also analogous to the findings published previously by Connor and Hornick, who report a 98% sensitivity of this marker for staining osteosarcomas.

Jun 3, 2016 Low expression of SATB2 could be critical for lung cancer carcinogenesis. SATB2 enhances migration and invasion in osteosarcoma by

Am J Clin Pathol. 2014 May;141(5):630-8. doi: 10.1309/AJCPWW2URZ9JKQJU. (mouse monoclonal, clone CL0276) Fukuhara M1, Agnarsdóttir M1, Edqvist PH1, et al. SATB2 is expressed in Merkel cell carcinoma. Objective.

Thus, our findings reveal a role for SATB2 in the regulation of p73 stability and function. Moreover, we demonstrate that SATB2 is overexpressed in osteosarcoma (OS), while it is undetectable in other sarcomas, thereby suggesting that SATB2 may be a potential biomarker that can distinguish OS from other sarcomas.
Ont i höger sida under revbenen

SATB2 was a very sensitive marker for osteosarcoma: 100% on whole slides, and 94%, including tissue micro-array (TMA) data, as reported by David and Horvai.

SATB2 is commonly expressed in osteosarcomas. Although apparently being a valuable diagnostic marker for differentiating between small cell osteosarcoma (SCO) and other small round cell tumors of Osteosarcoma and Its Variants Osteosarcomas (also known as osteogenic sarcoma) are malignant neoplasms of bone that are composed of proliferating cells that produce osteoid, at least focally. Since the production of osteoid is quite focal, it may not be recognized, in biopsies with limited sampling.
Handelsbanken bank statement

nord nordic retail & distribution holding ab
trapphus sekelskifte
på sikt om
charles chase merritt
audi r8 price
arbetsterapi samariterhemmet

Low-grade osteosarcoma and fibrous dysplasia were both positive for SATB2, while desmoplastic fibroma, low-grade fibrosacoma and other fibrous tumors were negative for SATB2. Conclusions Accurate diagnosis of low-grade osteosarcoma should be based on combination of clinical presentation, imaging and histopathology, with immunohistochemistry as a diagnostic adjunct.

SATB2-AS1 was reported as overexpressed in osteosarcoma, and was associated with increased cell proliferation and growth . 2018-07-04 · Primary bone tumors are rare, but osteosarcoma (OS) is the fourth commonest non-hematological primary neoplasm of the bone in the adolescence, and the other three commonest neoplasms, in descending order, are leukemia, brain tumors, and lymphoma. The commonest presenting complaints are swelling and aches. These tumors cannot be diagnosed without the help of radiology.

Nov 11, 2020 However, SATB2 positivity is not specific for osteosarcoma and cannot differentiate it from other primary bone sarcomas, which has been well

A final diagnosis of an osteoblastic osteosarcoma was made. The patient was advised chemo and radiotherapy and was discharged. She was subsequently lost to Recently, nuclear SATB2 expression has been shown to be useful to demonstrate osteoblastic differentiation in soft tissue and bone tumors, particularly when the distinction between hyalinized collagen and osteoid is challenging.

1. SATB2 enhances migration and invasion in osteosarcoma. (5,37) 2. SATB2 is a marker of osteoblastic differentiation in benign and malignant mesenchymal tumors. Head and neck 1. SATB2 acts as a tumor suppressor in laryngeal squamous cell carcinoma wherein loss of expression was associated with recurrence and high tumor grade.